Clinical Trial Update: A Study of Benralizumab in Patients With Eosinophilic Esophagitis [Phase 3]

View source ↗

Summary

Phase 3 trial of benralizumab in eosinophilic esophagitis was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Esophagitis

Drugs mentioned

• Benralizumab (benralizumab)

Snippet

Sponsor: AstraZeneca | Conditions: Eosinophilic Esophagitis | Phase 3 | Status: TERMINATED | Results posted: 2023-11-18